

--22. (New) A composition for inducing specific B cell anergy to a T cell dependent immunogen implicated in an antibody-mediated pathology comprising a plurality of a conjugate, wherein said conjugate comprises:

at least two analog molecules of the immunogen conjugated to a chemically defined valency platform molecule, wherein said analog molecules bind specifically to surface antibody on B cells to which the T cell-dependent immunogen binds specifically, and wherein the analog molecules lack T cell epitopes;

wherein the chemically defined valency platform molecule comprises branching groups, and wherein the valency platform molecule contains a specific number of attachment sites whereby the valency of said platform molecule is defined; and

wherein the molecular weight of the valency platform molecules is substantially homogeneous; and

wherein the valency platform molecules have attachment sites at the same location.

23. (New) The composition of claim 22, wherein the branching groups are derived from a functional group selected from the group consisting of diamino acid, triamine, and amino diacid.

24. (New) The composition of claim 22, wherein the analog molecules are the same.

25. (New) The composition of claim 22 comprising conjugates, wherein a said conjugate comprises four analog molecules.

26. (New) The composition of claim 22, wherein the analog molecule is selected from the group consisting of carbohydrates, lipids, lipopolysaccharides, polypeptides, peptides, proteins, glycoproteins, and lipoproteins.

27. (New) The composition of claim 22, wherein the valency platform molecules are substantially non-immunogenic.

28. (New) The composition of claim 22, wherein the analog molecule is a protein.
29. (New) The composition of claim 22, comprising a pharmaceutically acceptable carrier.
30. (New) The composition of claim 29, wherein the composition is suitable for injection.
31. (New) The composition of claim 22, wherein the conjugate comprises polyethylene glycol.
32. (New) The composition of claim 22, wherein the valency platform molecule comprises polyethylene glycol.
33. (New) The composition of claim 22, wherein the conjugate comprises polyethylene glycol having the formula  $-\text{CH}_2(\text{CH}_2\text{OCH}_2)_r\text{CH}_2-$ , wherein  $r=0$  to 300.
34. (New) The composition of claim 22, wherein the valency platform molecule comprises polyethylene glycol having the formula  $-\text{CH}_2(\text{CH}_2\text{OCH}_2)_r\text{CH}_2-$ , wherein  $r=0$  to 300.
35. (New) The composition of claim 22, wherein the valency platform molecule comprises triethylene glycol.
36. (New) The composition of claim 22, wherein the antibody mediated pathology is stroke.
37. (New) The composition of claim 22, wherein the immunogen is an external immunogen.

38. (New) The composition of claim 37, wherein the external immunogen is a biological drug, allergen or a D immunogen associated with Rh hemolytic disease.

39. (New) The composition of claim 22, wherein the immunogen is a self-immunogen.

40. (New) The composition of claim 39, wherein the immunogen is a cardiolipin.

41. (New) The conjugate of claim 39, wherein the self-immunogen is that associated with thyroiditis, diabetes, stroke, male infertility, myasthenia gravis, or rheumatic fever.

42. (New) The composition of claim 22, wherein the immunogen and analog molecules are same chemical class.

43. (New) The composition of claim 42, wherein the immunogen and the analog molecules are polypeptides.

44. (New) The composition of claim 22, wherein the immunogen and the analog molecules are of different chemical classes.

45. (New) The conjugate of claim 22, wherein the antibody-mediated pathology is an autoimmune disorder and the associated immunogen is unidentified.

46. (New) The conjugate of claim 22, wherein the analog molecules are selected from the group consisting of peptides, polypeptides, and proteins.

47. (New) The conjugate of claim 22, wherein the analog molecules are selected from the group consisting of glycoproteins, lipoproteins, carbohydrates, lipids and lipopolysaccharides.

48. (New) A method of inducing specific B cell anergy to a T cell-dependent immunogen in an individual comprising administering to the individual an effective amount of the composition of claim 29.

49. (New) A method of treating an individual for an antibody-mediated pathology in which undesired antibodies are produced in response to a T cell-dependent immunogen comprising administering a therapeutically effective amount of the composition of claim 29 to the individual.

50. (New) A method of making the composition of claim 22, the method comprising forming the conjugates by covalently bonding the analog molecules to the valency platform molecule.

51. (New) A method of making the composition of claim 29, the method comprising combining the conjugates with a pharmaceutically acceptable carrier.